Stay updated with breaking news from Abdul Mullick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Joint Venture Collaboration includes a portfolio of 13 life-changing brands across six therapeutic areas, with revenues primarily resulting from pain management medicines The collaboration
CRYSVITA is the first approved biologic treatment in the EU for patients with TIO who cannot undergo surgical removal of tumours Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that
CRYSVITA could offer access to the first biologic treatment for EU patients with TIO who cannot undergo surgical removal of tumours Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that
CRYSVITA could offer access to the first biologic treatment for EU patients with TIO who cannot undergo surgical removal of tumours Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that
Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.